

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis ID3748

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Janssen (daratumumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Addenbrookes Liver Transplant Association • Arthritis and Musculoskeletal Alliance • British Liver Trust • Cardiomyopathy UK • Cardiovascular Care Partnership • GUTS UK • Kidney Care UK • Kidney Research UK • Liver4Life • Muslim Council of Britain • Myeloma UK • National Kidney Federation • Pain Concern • Pain Relief Foundation • Pain UK • Polycystic Kidney Disease Charity • Pumping Marvellous Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • UK ATTR Amyloidosis Patients' Association • UK Primary Immunodeficiency Network • WMUK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Renal Technologists • British Association for the Study of the Liver • British Association of Urological Nurses 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information's Services – Jehovah's Witnesses • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • ADVANZ Pharma (dexamethasone) • Aspen (dexamethasone, melphalan) • Aspire Pharma (bortezomib) • Baxter Healthcare (cyclophosphamide) • Consilient Health (dexamethasone) • Dr Reddy's Laboratories (bortezomib) • Glenmark Pharmaceuticals Europe (dexamethasone) • Hameln pharmaceuticals (dexamethasone) • Hospira UK (dexamethasone)

Final stakeholder list for the technology appraisal of daratumumab in combination for untreated systemic amyloid light-chain amyloidosis ID3748. Issue date: July 2020.

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Liver Nurses Forum • British Myology Society • British Orthopaedic Association • British Pain Society • British Renal Society • British Society of Rehabilitation Medicine • British Society for Haematology • British Society for Heart Failure • Neuromodulation Society of UK and Ireland • Physiotherapy Pain Association • Renal Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • UK Clinical Pharmacy Association • UK Renal Pharmacy Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Leeds CCG • NHS Vale Royal CCG • Welsh Government 	<ul style="list-style-type: none"> • Martindale Pharma (dexamethasone) • Novartis Pharmaceuticals (dexamethasone) • Janssen-Cilag (bortezomib) • Panpharma UK (dexamethasone) • Rosemont Pharmaceuticals (dexamethasone) • Sandoz (cyclophosphamide) • Sun Pharmaceutical (melphalan) • Thame Laboratories (dexamethasone) • Thea Pharmaceuticals (dexamethasone) • Thornton & Ross (bortezomib) • Tillomed Laboratories (melphalan) • Wockhardt UK (dexamethasone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • Cochrane Kidney and Transplant Group • Cochrane Hepato-Biliary Group • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Foundation for Liver Research • Genomics England • Orthopaedic Research UK • MRC Clinical Trials Unit • National Institute for Health Research • Pain Relief Foundation <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.